Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 5 (May)

1. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
   J Clin Oncol, 25(13): 1670-6. [Abstract] [Full-text]
2. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
   J Clin Oncol, 25(13): 1658-64. [Abstract] [Full-text]
3. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
   Oncologist, 12(4): 443-50. [Abstract] [Full-text]
4. Barriers to rehabilitation of colorectal cancer patients.
   J Surg Oncol, 95(5): 400-8. [Abstract] [Full-text]
5. The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases.
   FASEB J, 21(7): 1445-62. [Abstract] [Full-text]
6. Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients.
   J Surg Oncol, 95(6): 499-506. [Abstract] [Full-text]
7. The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: a population-based study in Greater Amsterdam.
   J Surg Oncol, 95(6): 447-54. [Abstract] [Full-text]
8. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors.
   Genes Chromosomes Cancer, 46(7): 644-55. [Abstract] [Full-text]
9. Microarray analysis to reveal genes involved in colon carcinogenesis.
   Expert Opin Pharmacother, 8(7): 895-900. [Abstract] [Full-text]
10. Selection of relevant genes in cancer diagnosis based on their prediction accuracy.
    Artif Intell Med, 40(1): 29-44. [Abstract] [Full-text]
11. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases.
    J Nucl Med, 48(5): 771-5. [Abstract] [Full-text]
12. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer.
    Cancer, 109(10): 1996-2003. [Abstract] [Full-text]
13. Local therapy for rectal cancer: still controversial?
    Dis Colon Rectum, 50(4): 523-33. [Abstract] [Full-text]
14. Combined abdominal and perineal approach for delayed restoration of bowel continuity after low anterior resection in females.
    Dis Colon Rectum, 50(4): 544-7. [Abstract] [Full-text]
15. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients.
    Dis Colon Rectum, 50(4): 478-88. [Abstract] [Full-text]
16. Laparoscopic resection in rectal cancer patients: outcome and cost-benefit analysis.
    Dis Colon Rectum, 50(4): 464-71. [Abstract] [Full-text]
17. Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells.
    Oncogene, 26(20): 2873-84. [Abstract] [Full-text]
18. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints.
    Oncogene, 26(20): 2914-24. [Abstract] [Full-text]
19. Bevacizumab in the treatment of colorectal cancer.
    Expert Opin Biol Ther, 7(5): 739-49. [Abstract] [Full-text]
20. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).
    Cancer Res, 67(9): 4382-9. [Abstract] [Full-text]
21. Identification of epigenetically silenced genes in tumor endothelial cells.
    Cancer Res, 67(9): 4138-48. [Abstract] [Full-text]
22. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
    J Am Coll Surg, 204(5): 753-61; discussion 761-3. [Abstract] [Full-text]
23. The SIL gene is essential for mitotic entry and survival of cancer cells.
    Cancer Res, 67(9): 4022-7. [Abstract] [Full-text]
24. Alternative splicing and nonsense-mediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript.
    Gene, 395(1): 8-14. [Abstract] [Full-text]
25. Surgery-derived reactive oxygen species produced by polymorphonuclear leukocytes promote tumor recurrence: studies in an in vitro model.
    J Surg Res, 140(1): 115-20. [Abstract] [Full-text]
26. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
    Cancer Lett, 251(2): 237-46. [Abstract] [Full-text]
27. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
    Clin Cancer Res, 13(9): 2758-67. [Abstract] [Full-text]
28. Managing older patients with colorectal cancer.
    J Clin Oncol, 25(14): 1891-7. [Abstract] [Full-text]
29. Adjuvant therapy in the elderly: making the right decision.
    J Clin Oncol, 25(14): 1870-5. [Abstract] [Full-text]
30. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma.
    Postgrad Med J, 83(979): 338-43. [Abstract] [Full-text]
31. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands.
    J Drug Target, 15(4): 311-9. [Abstract] [Full-text]
32. Poorly differentiated rectal carcinoid in a cow.
    Vet Pathol, 44(3): 414-7. [Abstract] [Full-text]
33. Primary care practice organization influences colorectal cancer screening performance.
    Health Serv Res, 42(3): 1130-49. [Abstract] [Full-text]
34. Socioeconomic and racial/ethnic differences in the discussion of cancer screening: "between-" versus "within-" physician differences.
    Health Serv Res, 42(3): 950-70. [Abstract] [Full-text]
35. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis.
    Clin Genet, 71(5): 427-33. [Abstract] [Full-text]
36. Genetic counselling and consent for tumour testing in HNPCC.
    Clin Genet, 71(5): 400-5. [Abstract] [Full-text]
37. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.
    Am J Gastroenterol, 102(5): 1070-6. [Abstract] [Full-text]
38. Midkine expression in colorectal tumors: correlation with Ki-67 labeling in sporadic, but not ulcerative colitis-associated ones.
    Pathol Int, 57(5): 260-7. [Abstract] [Full-text]
39. Malignancies of the colorectum and anus in solid organ recipients.
    Transpl Int, 20(6): 497-504. [Abstract] [Full-text]
40. Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma.
    Exp Mol Pathol, 82(3): 284-91. [Abstract] [Full-text]
41. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Cancer Chemother Pharmacol, 60(2): 275-83. [Abstract] [Full-text]
42. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
    Lancet, 369(9573): 1603-13. [Abstract] [Full-text]
43. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
    Int J Radiat Oncol Biol Phys, 68(2): 472-8. [Abstract] [Full-text]
44. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.
    Gastroenterology, 132(6): 2208-25. [Abstract] [Full-text]
45. Sphincter-preserving operations without defunctioning stoma.
    ANZ J Surg, 77(5): 381-4. [Abstract] [Full-text]
46. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells.
    Oncogene, 26(21): 3006-19. [Abstract] [Full-text]
47. Onerous concomitant complications of ulcerative colitis: a case report.
    Z Gastroenterol, 45(5): 379-81. [Abstract] [Full-text]
48. Rise of colorectal cancer in Singapore: an epidemiological review.
    ANZ J Surg, 77(6): 446-9. [Abstract] [Full-text]
49. Emerging therapies for colorectal cancer.
    Expert Opin Investig Drugs, 16(6): 867-76. [Abstract] [Full-text]
50. Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer.
    Br J Cancer, 96(10): 1605-12. [Abstract] [Full-text]
51. Colorectal tumors within an urban minority population in New York City.
    J Gen Intern Med, 22(6): 835-40. [Abstract] [Full-text]
52. BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees.
    J Invest Dermatol, 127(6): 1387-91. [Abstract] [Full-text]
53. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma.
    Cancer Immunol Immunother, 56(8): 1225-36. [Abstract] [Full-text]
54. Staged anterior resection and TEM to preserve rectal function in synchronous malignant and benign rectal lesions.
    Colorectal Dis, 9(5): 469-71. [Abstract] [Full-text]
55. Diagnostic value of self-reported symptoms in Danish outpatients referred with symptoms consistent with colorectal cancer.
    Colorectal Dis, 9(5): 443-51. [Abstract] [Full-text]
56. The role of primary tumour resection in patients with stage IV colorectal cancer.
    Colorectal Dis, 9(5): 430-7. [Abstract] [Full-text]
57. Following anterior resection for rectal cancer, defunctioning ileostomy closure may be significantly delayed by adjuvant chemotherapy: a retrospective study.
    Colorectal Dis, 9(5): 420-2. [Abstract] [Full-text]
58. Magnetic resonance imaging for preoperative staging of rectal cancer in clinical practice: high accuracy in predicting circumferential margin with clinical benefit.
    Colorectal Dis, 9(5): 412-9. [Abstract] [Full-text]
59. Diagnostic precision of magnetic resonance imaging for preoperative prediction of the circumferential margin involvement in patients with rectal cancer.
    Colorectal Dis, 9(5): 402-11. [Abstract] [Full-text]
60. Chemoprevention of colorectal cancer - a new target needed?
    Colorectal Dis, 9(5): 397-401. [Abstract] [Full-text]
61. MicroRNA-143 and -145 in colon cancer.
    DNA Cell Biol, 26(5): 311-20. [Abstract] [Full-text]
62. Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches.
    Colorectal Dis, 9(5): 393-6. [Abstract] [Full-text]
63. Current surgical management of rectal cancer.
    Dig Surg, 24(2): 115-9. [Abstract] [Full-text]
64. Surgical treatment for digestive cancer. Current issues - colon cancer.
    Dig Surg, 24(2): 108-14. [Abstract] [Full-text]
65. A 68-year-old man with COPD contemplating colon cancer surgery.
    JAMA, 297(19): 2121-30. [Abstract] [Full-text]
66. Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer.
    Oncogene, 26(23): 3387-94. [Abstract] [Full-text]
67. Perceptions of colon cancer screening by stage of screening test adoption.
    Cancer Nurs, 30(3): 178-85. [Abstract] [Full-text]
68. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Cancer Res, 67(10): 4949-55. [Abstract] [Full-text]
69. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Cancer Res, 67(10): 4940-8. [Abstract] [Full-text]
70. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
    Cancer Res, 67(10): 4860-8. [Abstract] [Full-text]
71. Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling.
    Cancer Res, 67(10): 4774-82. [Abstract] [Full-text]
72. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer.
    Cancer Res, 67(10): 4725-31. [Abstract] [Full-text]
73. Hint1 inhibits growth and activator protein-1 activity in human colon cancer cells.
    Cancer Res, 67(10): 4700-8. [Abstract] [Full-text]
74. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression.
    Cancer Res, 67(10): 4620-9. [Abstract] [Full-text]
75. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
    Mol Cancer Res, 5(5): 485-96. [Abstract] [Full-text]
76. Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles.
    Mol Cancer Res, 5(5): 461-71. [Abstract] [Full-text]
77. A multinational, internet-based assessment of observer variability in the diagnosis of serrated colorectal polyps.
    Am J Clin Pathol, 127(6): 938-45. [Abstract] [Full-text]
78. Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
    Eur J Haematol, 78(6): 543-4. [Abstract] [Full-text]
79. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach.
    BMC Cancer, 7: 69. [Abstract] [Full-text]
80. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
    Hum Pathol, 38(6): 850-6. [Abstract] [Full-text]
81. The MUC13 cell surface mucin is highly expressed by human colorectal carcinomas.
    Hum Pathol, 38(6): 883-92. [Abstract] [Full-text]
82. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Hum Pathol, 38(6): 842-9. [Abstract] [Full-text]
83. Peritoneal cytology in colorectal cancer: incidence and prognostic value.
    Am J Surg, 193(6): 672-5. [Abstract] [Full-text]
84. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5.
    J Biol Chem, 282(21): 15541-9. [Abstract] [Full-text]
85. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
    J Pathol, 212(2): 124-33. [Abstract] [Full-text]
86. Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability.
    Eur J Surg Oncol, 33(5): 580-5. [Abstract] [Full-text]
87. The role of cytoreductive surgery for colon cancer metastatic to the ovary.
    Gynecol Oncol, 105(3): 791-5. [Abstract] [Full-text]
88. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer.
    Eur J Surg Oncol, 33(5): 590-6. [Abstract] [Full-text]
89. Evidence for an association of human papillomavirus infection and colorectal cancer.
    Eur J Surg Oncol, 33(5): 569-74. [Abstract] [Full-text]
90. Quality of life outcomes following laparoscopic total mesorectal excision for low rectal cancers: a clinical control study.
    Eur J Surg Oncol, 33(5): 575-9. [Abstract] [Full-text]
91. Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.
    J Clin Pathol, 60(5): 534-9. [Abstract] [Full-text]
92. Comparative genomic instabilities of thyroid and colon cancers.
    Arch Otolaryngol Head Neck Surg, 133(5): 457-63. [Abstract] [Full-text]
93. Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival.
    Radiology, 243(3): 744-51. [Abstract] [Full-text]
94. Hepatic colorectal cancer metastases: imaging initial steps of formation in mice.
    Radiology, 243(3): 703-11. [Abstract] [Full-text]
95. Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
    Cytometry A, 71(6): 361-70. [Abstract] [Full-text]
96. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
    BMC Cancer, 7: 72. [Abstract] [Full-text]
97. Suxamethonium-induced hyperkalaemia 6 weeks after chemoradiotherapy in a patient with rectal carcinoma.
    Br J Anaesth, 98(6): 766-8. [Abstract] [Full-text]
98. Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years.
    Gut, 56(6): 863-8. [Abstract] [Full-text]
99. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm?
    Gut, 56(6): 838-46. [Abstract] [Full-text]
100. A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer.
     Ann Surg, 245(6): 867-72. [Abstract] [Full-text]
101. Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial.
     Ann Surg, 245(6): 858-63. [Abstract] [Full-text]
102. Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01.
     Ann Surg, 245(6): 846-57. [Abstract] [Full-text]
103. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
     N Engl J Med, 356(21): 2131-42. [Abstract] [Full-text]
104. Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer.
     Cancer, 109(11): 2161-70. [Abstract] [Full-text]
105. Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions.
     Cancer, 109(11): 2213-21. [Abstract] [Full-text]
106. Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer.
     Cancer, 109(11): 2222-8. [Abstract] [Full-text]
107. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
     Cancer, 109(9): 1750-5. [Abstract] [Full-text]
108. Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma.
     Cancer, 109(9): 1742-9. [Abstract] [Full-text]
109. Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression.
     J Pathol, 212(1): 83-90. [Abstract] [Full-text]
110. Pesticide use and colorectal cancer risk in the Agricultural Health Study.
     Int J Cancer, 121(2): 339-46. [Abstract] [Full-text]
111. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors.
     Int J Cancer, 121(2): 454-8. [Abstract] [Full-text]
112. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA.
     Int J Cancer, 121(2): 401-6. [Abstract] [Full-text]
113. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
     Int J Cancer, 121(2): 257-64. [Abstract] [Full-text]
114. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition.
     Int J Cancer, 121(2): 368-76. [Abstract] [Full-text]
115. In vitro differentiation of HT-29 M6 mucus-secreting colon cancer cells involves a trychostatin A and p27(KIP1)-inducible transcriptional program of gene expression.
     J Cell Physiol, 212(1): 42-50. [Abstract] [Full-text]
116. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality.
     Int J Cancer, 121(2): 232-40. [Abstract] [Full-text]
117. Chromosomal alteration in Chinese sporadic colorectal carcinomas detected by comparative genomic hybridization.
     Diagn Mol Pathol, 16(2): 96-103. [Abstract] [Full-text]
118. Limitations in molecular detection of lymph node micrometastasis from colorectal cancer.
     Diagn Mol Pathol, 16(2): 91-5. [Abstract] [Full-text]
119. Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
     Appl Immunohistochem Mol Morphol, 15(2): 175-80. [Abstract] [Full-text]
120. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
     Inflamm Bowel Dis, 13(4): 367-71. [Abstract] [Full-text]
121. Proteomic analysis of Tiam1-mediated metastasis in colorectal cancer.
     Cell Biol Int, 31(8): 805-14. [Abstract] [Full-text]
122. Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate.
     J Gastroenterol, 42(5): 402-5. [Abstract] [Full-text]
123. Association of tannase-producing Staphylococcus lugdunensis with colon cancer and characterization of a novel tannase gene.
     J Gastroenterol, 42(5): 346-51. [Abstract] [Full-text]
124. Role of human papillomavirus in squamous cell metaplasia-dysplasia-carcinoma of the rectum.
     Am J Surg Pathol, 31(6): 919-25. [Abstract] [Full-text]
125. Oral and maxillofacial manifestations of Gardner's syndrome associated with growth hormone deficiency: case report and literature review.
     Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103(6): e30-4. [Abstract] [Full-text]
126. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells.
     J Biol Chem, 282(22): 16006-15. [Abstract] [Full-text]
127. Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis.
     Am J Gastroenterol, 102(6): 1284-90. [Abstract] [Full-text]
128. Elucidating the interactions between the adhesive and transcriptional functions of beta-catenin in normal and cancerous cells.
     J Theor Biol, 247(1): 77-102. [Abstract] [Full-text]
129. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
     J Dig Dis, 8(2): 82-8. [Abstract] [Full-text]
130. Novel small molecule induces p53-dependent apoptosis in human colon cancer cells.
     Biochem Biophys Res Commun, 358(3): 842-7. [Abstract] [Full-text]
131. Solution structure of the all L- and D-amino acid-substituted mucin 2 epitope peptides.
     Biochem Biophys Res Commun, 358(3): 739-42. [Abstract] [Full-text]
132. Investigation of pathogenic mechanisms in multiple colorectal adenoma patients without germline APC or MYH/MUTYH mutations.
     Br J Cancer, 96(11): 1729-34. [Abstract] [Full-text]
133. N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice.
     Br J Cancer, 96(11): 1684-91. [Abstract] [Full-text]
134. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
     Br J Cancer, 96(11): 1750-4. [Abstract] [Full-text]
135. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial.
     Ann R Coll Surg Engl, 89(4): 418-21. [Abstract] [Full-text]
136. Long-term survival is possible after stenting for malignant ureteric obstruction in colorectal cancer.
     Ann R Coll Surg Engl, 89(4): 414-7. [Abstract] [Full-text]
137. Mesenteric extraskeletal osteosarcoma with telangiectatic features: a case report.
     BMC Cancer, 7: 82. [Abstract] [Full-text]
138. Colon cancer risk and different HRT formulations: a case-control study.
     BMC Cancer, 7: 76. [Abstract] [Full-text]
139. Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.
     J Clin Oncol, 25(16): 2313-21. [Abstract] [Full-text]
140. Initial report of PET/CT-guided radiofrequency ablation of liver metastases.
     J Vasc Interv Radiol, 18(6): 801-3. [Abstract] [Full-text]
141. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
     Hum Gene Ther, 18(5): 435-50. [Abstract] [Full-text]
142. Preoperative mechanical preparation of the colon: the patient's experience.
     BMC Surg, 7: 5. [Abstract] [Full-text]
143. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
     J Clin Oncol, 25(16): 2198-204. [Abstract] [Full-text]
144. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
     J Clin Oncol, 25(16): 2205-11. [Abstract] [Full-text]
145. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway.
     FASEB J, 21(8): 1730-41. [Abstract] [Full-text]
146. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice.
     Int J Cancer, 121(3): 506-13. [Abstract] [Full-text]
147. Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer.
     Int J Cancer, 121(3): 555-8. [Abstract] [Full-text]
148. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment.
     Int J Cancer, 121(3): 495-500. [Abstract] [Full-text]
149. Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer.
     Int J Cancer, 121(3): 486-94. [Abstract] [Full-text]
150. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers.
     Int J Cancer, 121(3): 567-75. [Abstract] [Full-text]
151. Role of S128R polymorphism of E-selectin in colon metastasis formation.
     Int J Cancer, 121(3): 528-35. [Abstract] [Full-text]

© 2004-2008 Colorectal Cancer Research Today. All Rights Reserved.